Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma

European Urology

Volumn 41, Issue 4, 2002, Pages 458-468

  Bohm M ^a   Ittenson, A ^a   Schierbaum, K F ^a   Rohl F W ^a   Ansorge, S ^a   Allhoff, E P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

CAM; Complementary and alternative medicine; Immune system; Immuno dysfunction; Immuno modulation; Interleukin 2; Kidney cancer

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MICROSOMAL AMINOPEPTIDASE; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MALE; MONOCYTE; NEPHRECTOMY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; B-LYMPHOCYTES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PREMEDICATION; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 0036555424     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00031-3     Document Type: Article

References (51)

1. Parry-Billings M, Baigrie RJ, Lamont PM, Morris PJ, Newsholme EA. Effects of major and minor surgery on plasma glutamine and cytokine levels. Arch Surg 1992;127:1237-40.
2. Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997;65:2283-91.
3. Allendorf JD, Bessler M, Whelan RL, Trokel M, Laird DA, Terry MB, et al. Postoperative immune function varies inversely with the degree of surgical trauma in a murine model. Surg Endosc 1997;11:427-30.
4. Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection. Surg Endosc 1998;12:963-7.
5. Gitzelmann CA, Mendoza-Sagaon M, Talamini MA, Ahmad SA, Pegoli Jr W, Paidas CN. Cell-mediated immune response is better preserved by laparoscopy than laparotomy. Surgery 2000;127:65-71.
6. Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, et al. Suppression of cellular immunity by surgical stress. Surgery 2000;127:329-36.
7. Leaver HA, Craig SR, Yap PL, Walker WS. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000;30:230-8.
8. Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff EP. Complex peri-operative immuno-dysfunction in patients with renal cell carcinoma. J Urol 2001;66:831-6.
9. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: Long-term results and prognostic factors. J Urol 1990;143:468-74.
10. Sánchez de la Muela P, Zudaire JJ, Robles JE, Rosell D, Aguera L, DeCastro F, et al. Renal cell carcinoma: Vena caval invasion and prognostic factors. Eur Urol 1991;19:284-90.
11. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma. J Urol 1991;146:1224-7.
12. Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C. Occurrence and localization of lymph node metastases in renal carcinoma. Scand J Urol Nephrol 1969;3:129-33.
13. Bilkenroth U, Taubert H, Riemanu D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. J Cancer 2001;92:577-82.
14. McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 1999;86:492-7.
15. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, et al. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 2000;6:3812-22.
16. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immuno-therapy with recombinant interleukin-2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992;52:5765-9.
17. Nichols PH, Ramsden CW, Ward U, Trejdosiewicz LK, Ambrose NS. Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol 1993;94:4-10.
18. Deehan DJ, Heys SD, Simpson W, Broom J, McMillan DN, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2. Br J Surg 1995;82:86-90.
19. Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio O, et al. Pre-operative interleukin-2 immuno-therapy induces eosinophilic infiltration in colorectal neoplastic stroma. Pathologica 1995;87:135-8.
20. Brivio F, Lissoni P, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immuno-therapy may prolong the survival time in advanced colorectal cancer patients. Oncology 1996;53:263-8.
21. Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F. Presurgical neuroimmuno-therapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ, editors. Therapeutic Potential of Melatonin, Vol. 23. Front Horm Res. Karger: Basel, 1997. p. 137-48.
22. Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer 1998;20:191-202.
23. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment, Publication No. 48. Geneva: World Health Organization, 1979.
24. 1. J Immunol Methods 1993;158:17-25.
25. SAS Institute Inc: SAS/STAT User's Guide, Version 6. Cary (NC): SAS Institute, 1994.
26. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, et al. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 1992;49:215-8.
27. Brivio F, Lissoni P, Barni S, Tancini G, Ardizzoia A, Erba L, et al. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: A phase 2 study. Eur J Surg 1993;159:43-7.
28. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668-72.
29. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient - Marker of injury or mediator of inflammation. Ann Surg 1996;224:647-64.
30. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-10.
31. Takenawa J, Kaneko Y, Okumura K, Yoshida O, Nakayama H, Fujita J. Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J Urol 1995;153:858-62.
32. Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso C-L, deKernion JB, et al. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol Immunother 1992;35:97-105.
33. Ulchaker JC, Klein EA. Biology of metastasis and its clinical implications: Renal-cell cancer. World J Urol 1996;14:175-81.
34. Hisano S, Sakamoto K, Ishiko T, Kamohara H, Ogawa M. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field. Cytokine 1997;9:447.
35. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immuno-therapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829-33.
36. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001;193:F5-9.
37. Roncarolo MG, Levings MK. The role of different subsets of T regulatory cells controlling autoimmunity. Curr Opin Immunol 2000;12:676-83.
38. Hunter JD. Effects of anaesthesia on the human immune system. Hosp Med 1999;60:658-63.
39. Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth 1997;78:201-19.
40. Gilliland HE, Armstrong MA, Carabine U, McMurray TJ. The choice of anesthetic maintenance technique influences the antiinflammatory cytokine response to abdominal surgery. Anesth Analg 1997;85:1394-8.
41. Kato M, Honda I, Suzuki H, Murakami M, Matsukawa S, Hashimoto Y. Interleukin-10 production during and after upper abdominal surgery. J Clin Anesth 1998;10:184-8.
42. Brix-Christensen V, Tonnesen E, Sørensen IJ, Bilfinger TV, Sanchez RG, Stefano GB. Effects of anaesthesia based on high versus low doses of opioids on the cytokine and acute-phase protein responses in patients undergoing cardiac surgery. Acta Anaesthesiol Scand 1998;42:63-70.
43. Stanojevic-Bakic N, Vuckovic-Dekic L, Radomirovic S, Juranic Z, Jovanovic N. The influence of surgery and anesthesia on lymphocyte functions in breast cancer patients: In vitro effects of indomethacin. Neoplasma 1999;46:54-60.
44. Southall JC, Lee SW, Bessler M, Allendorf JD, Whelan RL. The effect of peritoneal air exposure on postoperative tumor growth. Surg Endosc 1998;12:348-50.
45. Fornara P, Doehn C, Seyfarth M, Jocham D. Why is urological laparoscopy minimally invasive? Eur Urol 2000;37:241-50.
46. Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Ströhlein MA, et al. Modulation of immune response by blood transfusion: Evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery. Shock 1997;8:402-8.
47. Ishijima N, Suzuki H. Blood transfusion and postoperative serum interleukin-6 levels in colorectal cancer patients. Hepatogastroenterology 1998;45:1011-3.
48. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-9.
49. Song GY, Chung C-S, Chaudry IH, Ayala A. What is the role of interleukin 10 in polymicrobial sepsis: Anti-inflammatory agent or immunosuppressant. Surgery 1999;126:378-83.
50. American Cancer Society. Guide to Complementary and Alternative Cancer Methods. Atlanta (GA): American Cancer Society, 2000. http://www.cancer.org.
51. Fair WR. Back to the future - The role of complementary medicine in urology. J Urol 1999;162:411-20.